Plain-English translation of NCT04808323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of radiation therapy called MRI-guided adaptive radiation therapy for people with locally advanced rectal cancer (stages I–III). Instead of traditional radiation treatment, this approach uses real-time MRI imaging to precisely target the tumor with higher doses of radiation while the treatment is happening, which may help shrink the cancer and preserve the rectum so surgery can be avoided.
Most people with advanced rectal cancer currently need surgery to remove the rectum, which can affect bowel function and quality of life. This trial exists to see if delivering higher, more precise radiation doses using new imaging technology might be strong enough to cure the cancer without surgery.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy over several weeks (typically 6–7 weeks depending on which dose group you are in), with treatment sessions 5 days a week. Before and during treatment, you will have MRI scans to help doctors precisely target the radiation. You will also have blood tests and imaging scans to monitor your health and how the cancer is responding. The study team will track you closely for any side effects and will check whether the tumor shrinks without needing surgery.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States